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Developing early detection biosensors for disease has been the long-held goal of the Human Genome Project, but
with little success. Conversely, the biological properties of the mitochondrion coupled with the relative simplicity of
the mitochondrial genome give this organelle extraordinary functionality as a biosensor and places the field of
mitochondrial genomics in a position of strategic advantage to launch significant advances in personalized
medicine. Numerous factors make the mitochondrion organelle uniquely suited to be an early detection biosensor
with applications in oncology as well as many other aspects of human health and disease. Early detection of
disease translates into more effective, less expensive treatments for disease and overall better prognoses for those
at greater risk for developing diseases.
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Nascentes Morimur—from the moment we are born, we
begin to die. This Latin phrase succinctly expresses the
motivations behind personalized medicine and genomic
research. The goal is to detect the earliest indications of
disease process initiation within the human body and
prevent disease advancement through early treatment.
Ideally, this leads to extended human life spans coupled
with enhanced quality of life. While the genetic root of
many diseases has been known for decades, the ‘-omics’
revolution starting with the Human Genome Project
(HGP) was the flashpoint that began the personalized
medicine movement.
Direct medical advances resulting from the HGP
have been minimal compared to the expectations of
its champions. Most currently available gene-specific
treatments for cancers, novel therapies for inherited
disorders, companion diagnostic genetic markers for
drug responsiveness, and gene-based risk assess-
ments for specific diseases are founded on research
that predates the HGP. Very little HGP research has
made the transition into practical use in the clinical
setting [1].
The greatest hindrance has been the sheer expansive-
ness of the human genome. Consisting of nearly 6 billion* Correspondence: r.parr@mitomicsinc.com
Mitomics Inc, Thunder Bay, Ontario P7A 7T1, Canada
© 2012 Parr and Martin; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the orbase pairs (bp), finding specific and actionable connec-
tions with diseases requires filtering through enormous
data sets. Scientists are still developing tools to decipher
this information, and applications in the clinical setting
are not yet a reality, despite the cost of sequencing an
entire genome now at about $1,000.
However, there is a branch of genomic research, spe-
cifically mitochondrial genomics (mtgenomics), that is
poised to begin entering clinical practice, and in some
instances, it already has. Though much emphasis was
initially placed on the HGP as a paradigm shift in mod-
ern medicine, this declaration would more accurately be
made of mtgenomics for a number of reasons that will
be outlined in this article.
Simply stating that a new technology or field of know-
ledge represents a paradigm shift in medicine does not
justify its adoption into mainstream medical practice. Util-
ity must be shown on a number of levels. This paper out-
lines why the mitochondrion organelle is a suitable
biosensor for detecting the early onset of disease; how its
use could decrease the cost of health care or lessen the
impact of disease; and how a mitochondrion biosensor
can be utilized to detect a range of disorders, for which
oncology will be presented as an example throughout this
article.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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The field of mtgenomics, from its inception in 1909 with
the discovery of extranuclear inheritance to the com-
pleted sequencing of the human mitochondrial genome
(mtgenome) in 1981, has been firmly established as a
primary arena for the development of genomic biosen-
sors for early cancer detection. Although mtgenomics
has been overshadowed in the last two decades by the
extraordinary amount of funding and effort directed to-
ward the HGP, it is a more practical backdrop for the
discovery and implementation of diagnostic and early
detection tools for numerous types of cancers. Historic-
ally, cancers such as ovarian, prostate, and colorectal
cancer have been very difficult to detect before a devas-
tating prognosis is the result. Utilizing the entire genome
of the mitochondrion as a biosensor to detect the onset
of these and other diseases is a highly significant medical
advancement that could save lives and also makes sound
economic sense.
The prospect of discovering countless treatments and
possibly even cures for diseases that have a genetic or
heritable origin has always surrounded the HGP. Early
on genomics was hailed as the beginning of a medical
revolution where personalized medicine or health care
and treatments tailored to individual genomic profiles
would become the norm. However, the enormity and
complexity of the human genome, comprised of over 6
billion base pairs, have made this task of developing new
medical therapies more complex than originally antici-
pated by many. What was initially acclaimed as a para-
digm shift in modern medicine has become a long
process and has necessitated additional programs such
as the sequencing of disease specific genomes and
characterization of the proteasome as well. Currently,
risk assessments based on nuclear genomic data can do
little more than provide motivation to encourage diet
and lifestyle changes, and since this can be suitably
addressed through public wellness campaigns, it
becomes hard to justify the expense of offering complete
routine genomic evaluations in medicine.
Paradigm shifts are not sudden rearrangements of the
world order. They are in fact a series of concepts, theor-
ies, and discoveries that gradually build upon one an-
other until enough knowledge accumulates for a larger
picture to emerge. The function of all the constituent
parts must be understood before an understanding of
the overall form can be achieved. When this process of
dissection has been completed, in theory, a map should
exist that delineates links between each of those parts
and their function. How fast these paradigm shifts can
occur is directly related to the complexity of the object
of study. In stark contrast to the nuclear genome, the
human mtgenome is composed of 16,568 base pairs and37 genes, which by comparison is strikingly simple. If
one were to anticipate a paradigm shift towards persona-
lized medicine, particularly where tools for detecting the
onset of diseases such as cancer are concerned, a logical
place to look would be within the field of mtgenomics.
Mathematically, the odds favor a mtgenomic solution.
This is suggested by the compactness of the mtgenome
and exemplified by mtDNA mutations found in associ-
ation with numerous diseases, including cancer. A
detailed review of these oncologic associations has been
presented by Parr et al. in 2007 [2].
mtGenomics is also favored by time since paradigm
shifts are not sudden events, but rather the culmination
of a series of discoveries and innovations. In 1981, the
entire mtgenome was already sequenced, but it would
not be until 2006, a full quarter of a century later, when
the complete human genome would be sequenced. The
field of mtgenomics has had more time to mature, giving
scientists substantial opportunities to understand the in-
tricacies of this knowledge base. The benefit of lead time
combined with the relative simplicity of the mtgenome
and specific biological properties of the mitochondria
gives mtgenomics a significant advantage over the larger
field of genomics when prospecting for biosensors, espe-
cially since mitochondrion organelles can be utilized col-
lectively as a biosensor. From this standpoint, mtgenomics
may become an organizational model for the larger body
of data that is the HGP.
Table 1 [3-8] provides a brief overview of the most sig-
nificant events in the development of mtgenomics, and
for comparison, it includes some of the more recent
milestones in the field of genomics.
Mitochondrial genomics and biosensor
prospecting
Utilizing mtgenomics as a clinical tool to detect the
onset of disease is part of a larger shift towards preven-
tion in medicine. Western medical systems have trad-
itionally focused on treating disease once symptoms
have become overt and often acute. This is not a func-
tion of intent but a result of the primary diagnostic tools
at hand. Instruments like the microscope and stetho-
scope were the only means of detecting disease available
to physicians prior to about 1895 when X-rays came into
use. X-ray technology made it possible to see into the
body without creating a surgical opening; however, its
utility was limited primarily to visualizing bones and the
outline of dense masses. Until the mid 1950s with the
founding of companies like the Thermo Electron Cor-
poration and the subsequent increased access to mass
spectrometric instruments, even physiologists primarily
conducted nutritional studies by direct physical observa-
tion and measurement. However, from this point on,
various types of instrumentation began to develop that
Table 1 Milestones in mitochondrial genomics
Year Milestone
1909 Correns and Baur independently identify the first cases of
extranuclear inheritance
1934 Goldschmidt suggests that causes for color differences in
gypsy moths may reside in the mitochondria
1940 Winge and Laustsen observe ‘inbreeding degeneration’ in
diploid yeast which they suggest is due to mitochondrial
heredity
1944 Slaughter presents the idea of field cancerization in oral cancer
1949 Ephrussi uses genetic analysis to show that respiration-
deficient baker's yeast is due to mutations in the cytoplasm,
not the nucleus. Soon after, Slonimski and Ephrussi show the
deficiency is due to mitochondrial dysfunction
1953 Slaughter formalizes the concept of field cancerization as
preconditioning of tissues for the onset of an ‘as-yet-unknown
carcinogenic agent’ which later turns out to be mitochondrial
mutation
1963 Nass and Nass use an electron microscope to show that chick
embryo mitochondria contain DNA




Groundwork for the field of mitochondrial genomics is firmly
established
1981 Anderson et al. publishes the sequence and organization of
the human mitochondrial genome as 16,569 base pairs long
1990a The US Department of Energy and the National Institute of
Health present a 5-year plan to Congress for the Human
Genome Project
1999a Chromosome 22 becomes the first human chromosome to be
completely sequenced
2000a Working draft of the human genome is completed
2004a Human gene count estimated at 20,000 to 25,000
2006a Human genome completely sequenced in high resolution and
is about 3 billion base pairs long
aRecent milestones in genomics.
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ical analysis possible. This is the era in which mtge-
nomics came of age. Coinciding with the advent of
technology that made it possible to peer into the work-
ings of the human body from many different perspec-
tives, mtgenomics became part of the movement
towards developing preventive medicine as opposed to
being absorbed into acute care medicine.
There are a number of factors that make mitochon-
drion organelles well suited for use as a biosensor:
1. Mitochondria contain multiple copies of their own
genome, and each cell contains multiple
mitochondria, resulting in a 10- to 100-fold copy
advantage over nuclear DNA. This means that
smaller samples can yield reliable results, and body
fluids with low cellularity can be readily evaluated
for their mtgenomic content.2. Mitochondria have their own unique genome which
is transmitted clonally through the mother and
should remain the same from generation to
generation.
3. Mitochondria do not contain histones and are more
prone to somatic or spontaneous DNA mutations.
The rate of somatic mutation in mtDNA is 10- to
17-fold that of the mutation rate within nuclear
DNA. Hence, molecular changes associated with
malignant transformations may be detectable much
earlier in mtDNA than nuclear DNA.
4. Genomic deletions within mitochondria begin to
happen long before traditional histology can identify
disease. Biochemical signatures can identify genomic
deletions associated with a disease and predict its
onset much earlier than a pathologist can observe a
problem, thus creating a greater window of time for
treatment possibilities.
5. The cancerization field associated with
mitochondrial deletions provides a distinct
molecular signature that mtgenomic assessment can
detect. Though conventional histology of a biopsy
sample might not display evidence of malignancy, if
the tissue comes from an area that is within the
cancerization field, disease onset will be detectable
via this signature. Coupling conventional biopsy
methodology with mtgenomic assessment to detect
this cancerization field provides vital clinical
information.
6. The small size of the mtgenome (16,568 bp) places it
at a cost advantage compared to the nuclear genome
(6,000,000,000 bp) when it comes to analyses. Its
compact nature also makes it possible to analyze the
entire mtgenome rapidly to identify specific
molecular markers with great accuracy.
7. Somatic mutations which affect ATP synthesis by
inhibiting OXPHOS also increase the production of
reactive oxygen species (ROS) and promote tumor
cell proliferation. Detecting these mutations can
serve to identify the onset of cancer [9].
8. The mtgenome often displays heteroplasmy, a
subset of altered/deleted genomes within the
mitochondria. Human tumor tissues that have
undergone somatic mutations often display
heteroplasmy. Differential rates of heteroplasmy in
mitochondria are associated with specific types of
tumors and can be used to identify different types of
cancer [9].
9. Mutations in the mtgenome have been identified in
a wide variety of cancers [2]. Individual as well as
combinations of mtgenome deletions can accurately
detect cancerization field effects [10].
10.Mitochondria mediate multiple metabolic pathways
and are sensitive to physiological changes.
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function symbiotically, and their resulting interactions
make it possible to detect dysfunction within the cell.
Though mitochondria execute various metabolic func-
tions outside of the nucleus of a cell, including synthe-
sizing 95% of cellular metabolic fuel, 1,200 nuclear genes
drive and participate in mitochondrial function. While
there are 37 genes coded by the mitochondrial genome,
24 of these genes are dedicated to processing 13 genes
within the mtgenome that produce protein subunits es-
sential to electron transport. These 13 genes work in con-
cert with 93 nuclear proteins. Some mutations in
mitochondrial genes alter the biochemical behavior of the
overall mitochondrial/nuclear protein complexes, increas-
ing pools of ROS, which in turn enable tumor growth and
may bestow proliferative advantages to the cell [11]. Des-
pite its miniscule size and the small number of genes that
comprise the mtgenome, somatic alterations that occur in
this molecule directly contribute to tumorigenesis.
There is a deep body of literature describing
mitochondrial-nuclear interactions [e.g. 12-14]. The som-
atic mutations that alter these interactions occur very
early in the process of disease onset, even before histo-
pathological changes to cells and tissues are evident to the
pathologist. mtGenomic technology makes it possible to
exploit these molecular signatures as a biosensor for early
indications of disease—detection that would not otherwise
be possible for many disorders in the current clinical set-
ting [15]. For example, the sampling error of prostate bi-
opsy is reduced to a 3.4-kb mtgenome deletion which is
present in prostate tumor as well as the surrounding
normal-appearing tissue [16,17].
There are already mtgenomic tests available for the de-
tection of disease onset, such as Prostate Core Mitomic
Test™ (PCMT) offered by Mitomics™ (Thunder Bay, On-
tario, Canada). This test, as will other mtgenomic tests,
utilizes the cancerization field effect and mtDNA dele-
tions to anticipate the onset and/or presence of hidden
or occult cancer. Ideally, this test and others like it act
to identify changes in tissue biopsies or other types of
biological samples that are indicative of the onset of
tumorigenesis. Mitochondrion biosensor tests such as
these provide the largest time frame possible to ward off
the onset of disease or prevent it altogether (Figure 1).
mtGenomic and complete genomic evaluations will
eventually become available with standard medical eva-
luations and annual physicals. This will provide physi-
cians with comparative longitudinal genomic records
and enable the earliest possible routine identification of
somatic mutations and the initiation of disease pro-
cesses. It will also ensure that patients have access to the
latest preventative therapies developed in concordance
with the field of genomics. Having access to longitudinal
genomic records and targeted therapies ascertains thebest prognosis for patients. Targeted therapies attack
specific types of tissues and are often more tolerable sys-
temically than older chemotherapies which were
designed to be aggressive for treating diseases such as
cancer identified in acute stages of development.
Lessening personal and economic costs of disease
Though mtgenomics removes technological barriers for
developing early detection biosensor platforms, there are
also other considerations to be made. Specifically, devel-
oping tools for detecting diseases necessitates the need for
early response treatments. This is one of the primary rea-
sons why some of the first mtgenomic tests being devel-
oped are for various types of cancer. A number of cancers
are difficult to detect using standard medical investigative
practices because their symptoms do not become obvious
until they reach a very late stage and have become difficult
to treat. However, numerous chemopreventive treatments
can be used at the earliest stages of these diseases to either
suppress or prevent the initiation of carcinogenesis. These
treatments are suitable for those deemed at greater risk
for developing particular cancers but do not yet have any
indications of disease onset, and for those who have begun
to display signs of disease, these treatments may halt the
progression of precancerous lesions into cancer [18,19].
The National Cancer Institute (NCI) began conducting
research on chemopreventive compounds in the early
1980s. To date, about 400 compounds are being actively
studied as chemopreventive agents, and more than 40
compounds are being evaluated in a clinical trial setting.
Of those agents being studied in a clinical setting, five
classes of agents have shown promise, and the NCI con-
siders these classes of compounds to be priority sub-
stances for study [20]. Table 2 [20,21] briefly summarizes
these priority compounds.
Toxicity studies can also make use of mtgenomic re-
search. A crucial aspect of evaluating new chemical en-
tities (NCE) for their chemopreventive properties is
ensuring that while the compounds disrupt the advance of
the disease process, they do not also result in contraindi-
cations that are more damaging than the disease itself. A
major problem with many new compounds is perturb-
ation of mitochondrial function, resulting in toxic cellular
effects. Integrating mitochondrial function studies during
the early stages of NCE evaluation provides the opportun-
ity to identify toxic effects from these compounds before
they reach later stage development or even human trials.
This can save extraordinary amounts of research dollars
and time [23].
Additionally, mtgenomic research conducted along
with NCE evaluation can stratify the study population
into two groups—those that respond to the compound
and those that do not. This could keep many drugs from
being unnecessarily ejected from the NCE pipeline while
Figure 1 The cancerization field effect and prostate cancer. Real-time PCR can be used to identify underlying molecular alterations in
normal-appearing tissues, thereby detecting the presence of malignant cells via a cancerization field effect. Though prostate needle biopsy cores
may fail to collect a tumor sample, the chemical signature of the tumor cancerization field may be detected in these same samples, optimizing
the biopsy procedure and the outcome for the patient [16,17].
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results by removing non-responders from the study
population. This strategy has been used in breast cancer;
5–10% of women are homozygous for low-activity
CYP2D6 alleles, and these women cannot properly
metabolize Tamoxifen. For women with this genotype,
Raloxifene is the chemopreventive therapy of choice.
CYP2D6 protein has been indentified and is metabolic-
ally active in liver cell mitochondria and functional inTable 2 Priority cancer chemopreventive agents
Class of agent Chemica
Selective estrogen receptor
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spread clinical use.’
Moreover, it is of vital importance that drug discovery
regimes include comprehensive screening for mitochon-
drial toxicity to avoid failure in either industry standard or
regulatory programs. A classic example of this problem is
illustrated by nucleoside reverse transcriptase inhibitors
(NRTIs) used to treat HIV infection. NRTIs constrain
mtDNA replication resulting in a loss of mitochondria over
time, causing liver and muscle toxicity. Other examples in-
clude a statin (cerivastatin) and an antidiabetic agent (tro-
glitazone) that have been found to cause muscle toxicity
and hepatotoxicity, respectively, due to the negative effects
these drugs have on mitochondria [25]. The effect of
pharmacological agents on mitochondria is an ongoing
concern [26] especially where the majority of individuals
benefit while others experience severe contraindications
when taking such medications.
mtGenomics has the potential to make meaningful con-
tributions to the area of pharmacogenomics since patients
receive obvious benefits from this approach, but making
these options available begins with ensuring that the
process of disease onset is clearly understood. Michael B.
Sporn, former Chief of the Laboratory of Chemoprevention
at the NCI and the scientist who coined the term and
developed the concept of chemoprevention in the early
1970s, points out that ‘There is still tremendous resistance
to the idea of telling people they have early changes in their
cells that could someday lead to invasive cancer. The em-
phasis should be on suppressing carcinogenesis, the devel-
opment of cancer, before it becomes evident as invasive or
metastatic cancer. We need a whole educational mission to
get people to think about cancer before they go to the doc-
tor, for example, with a lump in their breast [27].’ For many
cancers, the molecular preamble leading to the discovery of
a physically observable malignant lesion generally occurs
over a 20- to 30-year period. This is a huge window of op-
portunity for detecting the onset of these diseases. Early de-
tection enables minimally invasive and generally well-
tolerated therapies for treatment of these diseases. This
means that the impact on quality of life for the patient is
minimized to the greatest extent possible.
The economic benefits are also clearly visible. The retail
cost for a 30-day supply of Tamoxifen is about $60, and a
5-year supply would cost about $3,700; a 30-day supply of
Raloxifene is about $97 with a 5-year supply cost of about
$5,800 [28]. Given that in 2006, the first year of treatment
for breast cancer in the US cost an average of $30,000 per
patient [29,30], utilizing options that prevent the need for
any kind of treatment beyond chemoprevention strategies,
and monitoring represents a savings to the health care sys-
tem of more than 80% in the first 12 months alone.
More broadly, figures from the American Cancer Society
[19] indicate that the total economic impact of cancer in2008 was $228.1 billion. Included in this were direct costs
of $93.2 billion, losses in productivity amounting to a cost
of $18.8 billion, and losses in productivity due to premature
death of $116.1 billion. Early screening to detect cancer
would significantly reduce losses due to lost productivity at-
tributable to sudden acute health crises for these patients
and due to premature death.
Substantial motivation exists for investing in the re-
search and development of early screening methodolo-
gies. Multi-billion-dollar screening markets exist for the
top five most prevalent cancers (lung, colon, breast,
prostate, and ovarian), ranging from $24 to $401 billion
dependent upon the final cost of the tests, which typic-
ally range from $100 to $3,500 dollars. Incidentally,
current early detection rates for these five types of can-
cer, though in some instances have improved over what
they were even 20 years ago, are still unacceptably low.
Mitochondrial genomics and human health
While a significant portion of biosensor research has fo-
cused on oncology, mtgenomics is applicable to human
health in general. Because mitochondria are responsible
for converting energy stores into a useable form for our
cells, any disorder that affects mitochondrial function
could be evaluated using mtgenomics. Mitochondrial
function disorders can be caused by mutations or dele-
tions occurring either in the mtgenome or in the nuclear
genome (occurring in genes that code for proteins that
contribute to mitochondrial function). Mutations in nu-
clear genes can be inherited from either parent, while
heritable mutations in the mtgenome will be transmitted
maternally. Heritable mtgenomic mutations can be iden-
tified by the presence of heteroplasmy; however, the de-
gree to which these disorders will affect mitochondrial
function is generally dependent on the degree of hetero-
plasmy. If enough copies of unaffected mtDNA are
present within a cell, these copies of mtDNA will com-
pensate for the dysfunction of the heteroplasmic copies
of mtDNA. Unless individuals with relatively minimal
levels of heteroplasmy undergo some sort of trauma or
extreme physiological stress that makes it impossible for
the unaffected mtDNA to compensate for the hetero-
plasmic DNA, overt indications of these disorders may
never occur. Assessing the degree of heteroplasmy may
help these individuals take preventative measures to en-
sure they minimize the possibility of experiencing such
physiological effects.
mtGenomic function may also be affected suddenly by
physiological traumas such as hemorrhage or a cardiac
event that induces hypoxia and forces mitochondrial
function to occur temporarily in an oxygen-reduced en-
vironment. These events may induce mitochondrial
damage similar to age-related declines in mitochondrial
function that, as free-radical theory-of-aging proponents
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to ROS [31]. Other diseases and conditions that increase
exposure to ROS and affect circulatory process, such as
diabetes mellitus, type II diabetes, and obesity, may also
contribute to cumulative disruptions in mitochondrial
function. Because the effects of many of these types of
disorders accumulate over time, associated somatic
mtDNA mutations will also likely accumulate over time.
Depending on the degree of severity of these conditions,
mitochondrial dysfunction and mtgenomic evidence of
dysfunction can occur at any age and ultimately drives
the aging process.
Many noncancerous clinical disorders have been asso-
ciated with mitochondrial dysfunction. Disorders involving
the brain and the heart, organs which are high consumers
of energy and would suffer from a downturn in mitochon-
drial production of energy, are notably present in this list.
Disorders falling into the neurological category include mi-
graine, strokes, epilepsy, dementia, myopathy, peripheral
neuropathy, speech disturbances, and sensorineural deaf-
ness. Cardiac disorders include heart failure, heart block,
and cardiomyopathy. Gastrointestinal conditions include
constipation and irritable bowel syndrome. Respiratory
conditions associated with mitochondrial dysfunction in-
clude respiratory failure, nocturnal hyperventilation, recur-
rent aspiration, and pneumonia. Endocrine disorders
include diabetes, thyroid disease, parathyroid disease, and
ovarian failure. Ophthalmological disorders include optic
atrophy, cataracts, and ophthalmoplegia [32]. While this
listing is not comprehensive, it shows that the effects of
mitochondrial dysfunction are far reaching. While preva-
lence varies in different populations, research suggests that
mtDNA disease is surprisingly high. For example, in a
working-age population (>16 and <60/65 years for female/
male patients, respectively) in the north east of England, 9.2
in 100,000 people were found to have manifest mtDNA dis-
ease [33].
Presently, mtgenomics is better situated than nuclear
genomics for the evaluation of mtDNA disorders due to
the smaller size of the mtgenome and number of constitu-
ent genes. However, evaluating mtDNA disorders is an area
of research where mtgenomics and nuclear genomics could
be applied in conjunction since a considerable number of
mitochondrial disorders are associated with nuclear genetic
inheritance. To exemplify this, the Mitochondria Phenome
Knowledgebase cites 174 genes that are associated with 502
different phenotypic features spanning the following
categories: oncologic, musculoskeletal, gastrointestinal,
respiratory, neurologic, ophthalmologic, genitourinary,
cardiovascular, hematologic, dermatologic, metabolic,
endocrinologic, immunologic, psychiatric, and numer-
ous miscellaneous categories [34].
While second-generation technologies have been use-
ful for mtgenomic and nuclear genomic discovery anddetermining the genetic basis of disease, the rapid action
and low cost of genomic sequencing that will become
available with third-generation genomic instrumentation
will make it possible to move those discoveries more
generally into the clinical setting and widespread med-
ical use [35].
It should not be overlooked that mtgenomics requires
careful experimental considerations. Population and
group variations in mtgenome sequences may alter or
preclude the absence or presence of a specific SNP or
deletion(s), leading to incorrect data interpretations for
certain populations. Mitochondrial sequencing data
must be compared to germ plasma on an individual pa-
tient basis if point mutations are to be used as a diag-
nostic reference. Using published mitochondrial genome
standards is inappropriate as these references are not
representative of either the individual or the specific dis-
ease under study. Moreover, mitochondrial pseudogenes
are embedded in the nucleus and often obscure results
or lead to inaccurate data interpretation since pseudo-
gene contamination is often mistaken for nucleotide het-
eroplasmy particularly in sequencing data [36]. This is a
noteworthy concern given the sensitivity of next-
generation sequencing technology as opposed to di-
deoxy chemistry, and extreme care must be taken to
preclude co-amplification of nuclear and mitochondrial
pseudogenes. Finally, caution is warranted when com-
paring malignant lesions and normal tissue from the
same organ and individual. The field effect is often op-
erative in the normal tissue and may have many muta-
tions in common with the tumor site. Use of normal
tissue as a comparative control may preclude reliable
results [10].Summary and conclusions
Both simplicity of structure and historical timing have
placed mtgenomics ahead of the HGP as a technology
leader for the development of early detection biosensors
for many diseases. Numerous mtgenomic-based tests are
currently in development, and some have already
entered the marketplace, signaling a transformation in
medicine towards prevention as the preferred strategy
for treating disease. Early detection biosensors have pre-
miered in oncology, as many types of cancer can be
associated with mtDNA deletions. Oncology-based che-
mopreventive strategies have been in development since
the 1970s and are now available to be paired with early
detection strategies. Following closely is the develop-
ment of biosensors for other mitochondrial disorders.
Since these disorders are more frequently hereditary
than are many cancers, examining them from the per-
spective of both mtgenomics and nuclear genomics will
provide insight into illness and also serve to develop
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data generated from the HGP.
Developing mtgenomic-based technologies presents
significant economic benefits for health care manage-
ment and the development of new drugs. Pairing
mtDNA studies with clinical trials stratifies study popu-
lations into responders and non-responders, making the
development and usage of these drugs as efficient and
effective as possible. Coupling this with the pending re-
lease of cheaper and faster third-generation sequencing
technologies creates an opportunity to make mtge-
nomic-based early detection biosensors widely available
in the near future. This stands to revolutionize the con-
ventional medical experience we are all familiar with
into a personalized experience specifically tailored to the
well-being of every individual.
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